Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diagnostics developer Cizzle Biotechnology said it had entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.
'The company's wholly owned subsidiary Cizzle Biotechnology was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley,' th ecompany said.
'The new agreement extends that relationship and provides seconded staff and access to the University's state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation partner Fairjouney Biologics,' it added